Literature DB >> 24175005

Prior Effective Sample Size in Conditionally Independent Hierarchical Models.

Satoshi Morita1, Peter F Thall, Peter Müller.   

Abstract

Prior effective sample size (ESS) of a Bayesian parametric model was defined by Morita, et al. (2008, Biometrics,64, 595-602). Starting with an ε-information prior defined to have the same means and correlations as the prior but to be vague in a suitable sense, the ESS is the required sample size to obtain a hypothetical posterior very close to the prior. In this paper, we present two alternative definitions for the prior ESS that are suitable for a conditionally independent hierarchical model. The two definitions focus on either the first level prior or second level prior. The proposed methods are applied to important examples to verify that each of the two types of prior ESS matches the intuitively obvious answer where it exists. We illustrate the method with applications to several motivating examples, including a single-arm clinical trial to evaluate treatment response probabilities across different disease subtypes, a dose-finding trial based on toxicity in this setting, and a multicenter randomized trial of treatments for affective disorders.

Entities:  

Keywords:  Bayesian hierarchical model; Computationally intensive methods; Conditionally independent hierarchical model; Effective sample size; Epsilon-information prior

Year:  2012        PMID: 24175005      PMCID: PMC3810292          DOI: 10.1214/12-BA720

Source DB:  PubMed          Journal:  Bayesian Anal        ISSN: 1931-6690            Impact factor:   3.728


  5 in total

1.  The role of meta-analysis in the regulatory process for foods, drugs, and devices.

Authors:  J A Berlin; G A Colditz
Journal:  JAMA       Date:  1999-03-03       Impact factor: 56.272

2.  Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes.

Authors:  Peter F Thall; J Kyle Wathen; B Nebiyou Bekele; Richard E Champlin; Laurence H Baker; Robert S Benjamin
Journal:  Stat Med       Date:  2003-03-15       Impact factor: 2.373

3.  Determining the effective sample size of a parametric prior.

Authors:  Satoshi Morita; Peter F Thall; Peter Müller
Journal:  Biometrics       Date:  2007-08-30       Impact factor: 2.571

4.  Continual reassessment method: a practical design for phase 1 clinical trials in cancer.

Authors:  J O'Quigley; M Pepe; L Fisher
Journal:  Biometrics       Date:  1990-03       Impact factor: 2.571

5.  A Bayesian analysis of institutional effects in a multicenter cancer clinical trial.

Authors:  R J Gray
Journal:  Biometrics       Date:  1994-03       Impact factor: 2.571

  5 in total
  9 in total

Review 1.  Bayesian methods in reporting and managing Australian clinical indicators.

Authors:  Peter P Howley; Stephen J Hancock; Robert W Gibberd; Sheuwen Chuang; Frank A Tuyl
Journal:  World J Clin Cases       Date:  2015-07-16       Impact factor: 1.337

2.  Detecting and accounting for violations of the constancy assumption in non-inferiority clinical trials.

Authors:  Joseph S Koopmeiners; Brian P Hobbs
Journal:  Stat Methods Med Res       Date:  2016-09-01       Impact factor: 3.021

3.  Borrowing Strength and Borrowing Index for Bayesian Hierarchical Models.

Authors:  Ganggang Xu; Huirong Zhu; J Jack Lee
Journal:  Comput Stat Data Anal       Date:  2020-04       Impact factor: 1.681

4.  A simulation study of methods for selecting subgroup-specific doses in phase 1 trials.

Authors:  Satoshi Morita; Peter F Thall; Kentaro Takeda
Journal:  Pharm Stat       Date:  2017-01-23       Impact factor: 1.894

5.  Evaluating the Impact of Prior Assumptions in Bayesian Biostatistics.

Authors:  Satoshi Morita; Peter F Thall; Peter Müller
Journal:  Stat Biosci       Date:  2010-07-01

6.  A Bayesian group sequential design for randomized biosimilar clinical trials with adaptive information borrowing from historical data.

Authors:  Wen Zhang; Zhiying Pan; Ying Yuan
Journal:  J Biopharm Stat       Date:  2022-06-09       Impact factor: 1.503

7.  Bayesian Group Sequential Clinical Trial Design using Total Toxicity Burden and Progression-Free Survival.

Authors:  Brian P Hobbs; Peter F Thall; Steven H Lin
Journal:  J R Stat Soc Ser C Appl Stat       Date:  2015-10-26       Impact factor: 1.864

8.  Motivating sample sizes in adaptive Phase I trials via Bayesian posterior credible intervals.

Authors:  Thomas M Braun
Journal:  Biometrics       Date:  2018-03-13       Impact factor: 1.701

9.  An adaptive power prior for sequential clinical trials - Application to bridging studies.

Authors:  Adrien Ollier; Satoshi Morita; Moreno Ursino; Sarah Zohar
Journal:  Stat Methods Med Res       Date:  2019-11-15       Impact factor: 3.021

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.